[go: up one dir, main page]

MX2010005545A - Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca. - Google Patents

Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca.

Info

Publication number
MX2010005545A
MX2010005545A MX2010005545A MX2010005545A MX2010005545A MX 2010005545 A MX2010005545 A MX 2010005545A MX 2010005545 A MX2010005545 A MX 2010005545A MX 2010005545 A MX2010005545 A MX 2010005545A MX 2010005545 A MX2010005545 A MX 2010005545A
Authority
MX
Mexico
Prior art keywords
heart failure
prophylaxis
treatment
oxazolidinones
disorders related
Prior art date
Application number
MX2010005545A
Other languages
English (en)
Inventor
Wolfgang Thielemann
Susanne Roehrig
Harald Kallabis
Elizabeth Perzborn
Dagmar Kubitza
Theodore Spiro
Lloyd Haskell
Jeet Mahal
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010005545A publication Critical patent/MX2010005545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de inhibidores selectivos del factor de coagulación Xa, en particular de oxazolidinonas de la fórmula (I), para el tratamiento y/o profilaxis de la insuficiencia cardiaca y/o trastornos relacionados con la insuficiencia cardiaca así como a su uso para la preparación de fármacos para el tratamiento y/o profilaxis de la insuficiencia cardiaca y/o trastornos relacionados con la insuficiencia cardiaca.
MX2010005545A 2007-12-11 2008-12-03 Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca. MX2010005545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US740607P 2007-12-11 2007-12-11
PCT/EP2008/010211 WO2009074249A1 (en) 2007-12-11 2008-12-03 Oxazolidinones for the treatment and/or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
MX2010005545A true MX2010005545A (es) 2010-07-30

Family

ID=40404481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005545A MX2010005545A (es) 2007-12-11 2008-12-03 Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca.

Country Status (18)

Country Link
US (1) US20110003804A1 (es)
EP (1) EP2229173A1 (es)
JP (1) JP2011506363A (es)
KR (1) KR20110010689A (es)
CN (1) CN101896185A (es)
AU (1) AU2008335922A1 (es)
BR (1) BRPI0820964A2 (es)
CA (1) CA2708418C (es)
DO (1) DOP2010000156A (es)
IL (1) IL205675A (es)
MA (1) MA31902B1 (es)
MX (1) MX2010005545A (es)
NZ (1) NZ586002A (es)
RU (2) RU2494740C2 (es)
SV (1) SV2010003578A (es)
TN (1) TN2010000266A1 (es)
UA (1) UA99638C2 (es)
WO (1) WO2009074249A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012321A1 (en) * 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Processes for crystallization of rivaroxaban
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
ES2911600T3 (es) * 2017-06-20 2022-05-20 Inst Nat Sante Rech Med Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
KR102715821B1 (ko) * 2017-11-09 2024-10-10 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
JP6574041B2 (ja) * 2017-12-15 2019-09-11 エルメッド株式会社 リバーロキサバン含有医薬組成物
SG11202003971RA (en) 2019-08-30 2021-04-29 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100257418B1 (ko) * 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra

Also Published As

Publication number Publication date
BRPI0820964A2 (pt) 2015-07-14
WO2009074249A1 (en) 2009-06-18
RU2010128442A (ru) 2012-01-20
RU2494740C2 (ru) 2013-10-10
IL205675A (en) 2013-10-31
IL205675A0 (en) 2010-11-30
DOP2010000156A (es) 2011-02-15
SV2010003578A (es) 2011-02-21
US20110003804A1 (en) 2011-01-06
UA99638C2 (ru) 2012-09-10
AU2008335922A1 (en) 2009-06-18
TN2010000266A1 (en) 2011-11-11
CN101896185A (zh) 2010-11-24
KR20110010689A (ko) 2011-02-07
JP2011506363A (ja) 2011-03-03
EP2229173A1 (en) 2010-09-22
CA2708418A1 (en) 2009-06-18
RU2013134140A (ru) 2015-01-27
CA2708418C (en) 2013-11-12
MA31902B1 (fr) 2010-12-01
NZ586002A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
IN2012DN01233A (es)
GB0625648D0 (en) Compounds
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
UA105036C2 (uk) Амінотетралінові похідні, фармацевтична композиція, яка їх містить, і їх застосування в терапії
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
NO20091655L (no) Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
NO20084328L (no) Nye forbindelser
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MX2009013501A (es) Compuestos piperidinicos y sus usos.
JO2645B1 (en) Vehicles
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MY150931A (en) Substituted oxazolidinones and their use
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: BAYER INTELLECTUAL PROPERTY GMBH